对过敏性鼻炎的潜在临床诊断和预后标志物的查和分析
Yejun Liu1, Yonggang Kong2, Xuhong Zhou3
1Department of Otolaryngology, Qianjiang Central Hospital Qianjiang 433100, Hubei, China.
American journal of translational research
|July 15, 2024
概括
这项研究确定了过敏性鼻炎 (AR) 预后的关键炎症标志物. 转化生长因子-β1 (TGF-β1),介素-13 (IL-13) 和血清免疫球蛋白E (IgE) 在AR患者中显示出显著的诊断和预后价值.
科学领域:
- 免疫学 免疫学 免疫学
- 临床医学 临床医学
- 生物标志物发现发现
背景情况:
- 过敏性鼻炎 (AR) 是一个重大的临床挑战.
- 确定可靠的AR诊断和预后标志物对于有效的患者管理至关重要.
研究的目的:
- 调查潜在的临床诊断和预后标志物对过敏性鼻炎 (AR).
- 分析AR患者队列中的炎症和临床标志物,以评估它们的有用性.
主要方法:
- 对493名AR患者的临床数据进行了回顾性分析.
- 根据治疗结果对患者进行分类.
- 评估各种炎症标志物 (IL-4,IL-5,TGF-β1,IL-13,组胺) 和血清IgE.
- 统计分析以确定诊断和预后意义.
主要成果:
- 在良好的和不良的预后组之间观察到TGF-β1,IL-13,组胺和血清IgE水平的显著差异.
- 血清IgE水平在预后不佳的组明显较高 (P < 0.001).
- 一个复合生物标志物模型实现了AR预后预测曲线下的面积为0.906.
结论:
- TGF-β1,IL-13和血清IgE是AR的有价值的诊断和预后指标.
- 综合生物标志物方法可以改善AR诊断和预后准确性.
- 建议进行进一步的前性研究,以验证这些发现并探索临床影响.
相关概念视频
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Asthma: Pathogenesis and Management
381
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
381
Drugs Used in Lower Respiratory Disorders: Overview
397
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
397
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
2.5K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
2.5K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
267
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
267
Allergic Reactions
27.3K
Overview
27.3K


